護城河比較

Narrow, not wide, because the FY2026 10-K documents a strong installed base and a competitive position the company itself says is under erosion. On the asset side: revenue of $4.7 billion (29% growth in each of the last three fiscal years), 13,328 total customers up from 10,996, 790 of the Forbes Global 2000 contributing about 43% of revenue, 733 customers above $1 million in trailing-12-month product revenue up from 576, a 125% net revenue retention rate, and more than 1,050 issued U.S. patents. Against that, Item 1A states plainly that adopting open data formats like Apache Iceberg means 'there is less customer “lock in” when our products are used in external environments' and that 'our support of open data formats may also reduce switching costs between us and our competitors'; that AWS, Azure and GCP 'generally compete in all of our markets' while also supplying the infrastructure a 'substantial majority of our business is run on'; and that the company remains loss-making at $1.3 billion of net loss for the year.

來源：sec.gov

The moat is narrow rather than wide. The filing names real entry barriers in launch — capital, technological expertise, licences and established government and commercial relationships — and adds spectrum and orbital resources in connectivity, while warning that the company's "leadership position in various markets, especially in orbital launch services" could attract competition-law scrutiny. The AI segment has barriers too: "Our AI businesses likewise compete in markets characterized by significant barriers to entry." Durability is capped by three-to-five-year satellite lives that force perpetual replacement launches, but the moat is not eroding: subscribers are 12.0M against 6.0M.

來源：sec.gov

The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed.

來源：sec.gov

The filing makes its own affirmative claim of network effects — 'Our business benefits from powerful network effects. ... The more customers adopt our platform, the more data can be exchanged with other Snowflake customers, partners, data providers, and data consumers' — but the load-bearing, quantified evidence in the document points to switching costs. The platform is sold as the way to 'consolidate data into a single source of truth,' and the disclosed economics of that consolidation are a 125% net revenue retention rate and 733 customers above $1 million in trailing product revenue. Item 1A confirms the mechanism by naming what is at risk: open formats produce 'less customer “lock in”' and 'may also reduce switching costs.' The filing frames lock-in, not network density, as the thing erosion would take away.

來源：sec.gov

The advantage is cost and scale. The stated model is extreme vertical integration plus reusability driving unit cost down: per NASA, the first Falcon 9 cut launch cost to about $2,700/kg, roughly 85% below the $18,500/kg historical average, and Falcon 9 has "demonstrated the ability to refly a first-stage 34 times" (3/31/26). The filing credits rising cadence, cargo capacity and "declining unit costs—driven by rapid reusability—have generated a compounding competitive advantage". SpaceX also launches its own constellation, and Competition notes "some of these service providers are also launch customers of SpaceX". Spectrum and licence intangibles reinforce the cost advantage.

來源：sec.gov

The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section.

來源：sec.gov

The 10-K contains no ranking, market-share figure, or claim of leadership, and it names no non-hyperscaler competitor by name. The band rests on disclosed scale — $4.7 billion of revenue, 13,328 customers, 9,060 employees across 36 countries — set against the filing's own statement that 'many of our competitors have substantially greater brand recognition, customer relationships, and financial, technical, and other resources than we do.' Co-leader among independent cloud data platforms; not a leader over AWS, Azure and GCP, which the filing says compete in all of its markets.

來源：sec.gov

SpaceX leads clearly in its two established segments but not in its newest. The prospectus calls it "the primary launch provider for the U.S. government" — 11 of 12 NSSL medium and heavy lift missions and all five U.S. crew and cargo ISS missions for NASA in 2025 — and says Starlink is "the sole low-latency network available globally", low-latency self-defined as under 70ms; it flags competition-law scrutiny risk from that leadership. AI is the exception, with OpenAI, Anthropic, Google, Meta and Microsoft named as competitors, some with greater resources, in a segment the filing calls early stage. Cadence slipped: H1 2026 Falcon launches 77 versus 81, mass to orbit 1,041t versus 1,102t.

來源：sec.gov

The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.'

來源：sec.gov

The consumption model plus 125% net revenue retention shows real expansion pricing, and the filing argues it competes on 'pricing transparency and optimized price-performance.' But Item 1A limits how far that goes: competition 'may negatively impact our ability to acquire new customers ... put downward pressure on our prices and gross margins'; the company 'may not be able to ... offer as many discounts or free services as our competitors'; results depend on 'changes in our pricing model, including in response to significant price discounts by our competitors' and on 'customer optimization efforts that result in reduced consumption.' On the cost side, 'our costs and gross margins are significantly influenced by the prices we are able to negotiate with these public cloud providers, which in certain cases are also our competitors.'

來源：sec.gov

Pricing power is moderate — a deliberate give-back from a cost position rather than weakness. Management states its strategy is "rather than prioritizing increases in ARPU" and expects Starlink ARPU to keep declining as it adds lower-priced plans and adjusts monthly service fees; the Q2 10-Q shows ARPU of $66 versus $85 while Connectivity operating income rose 79.4%. Launch sells on fixed-price contracts, one to five years for Launch Services and up to fourteen for Launch and Development. Concentration is material: about one-fifth of 2025 revenue came from U.S. federal agencies, with all launch contracts firm fixed-price and terminable at the government's convenience without advance notice.

來源：sec.gov

Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price.

來源：sec.gov

Sits at the enterprise data and governance layer of the AI stack, and the AI exposure is explicit rather than incidental: the filing brands the product the 'AI Data Cloud,' lists AI as a product category, and put Snowflake Intelligence, Cortex Agents and a Managed MCP Server into general availability during the fiscal year. It is a buyer of hyperscaler compute and of third-party frontier models — 'strategic partnerships with foundational model providers deliver state-of-the-art models natively within Snowflake Cortex AI,' with stated 'model neutrality' — and a supplier of governed enterprise data and GPU-backed managed compute to AI applications built on top.

Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells.

• Analytics 前三 · 深 來源：sec.gov
• Data Engineering 挑戰者 · 中等 來源：sec.gov
• Snowflake Cortex AI 挑戰者 · 中等 來源：sec.gov
• Snowflake Marketplace and Data Collaboration 領先 · 深 來源：sec.gov
• Snowflake Postgres and Unistore 利基市場 · 低 來源：sec.gov
• Snowpark and Native Application Framework 利基市場 · 中等 來源：sec.gov

• AI compute infrastructure (COLOSSUS) 挑戰者 · 低 來源：sec.gov
• Dragon crew and cargo spacecraft 領先 · 深 來源：sec.gov
• Falcon 9 / Falcon Heavy launch services 領先 · 深 來源：sec.gov
• Grok frontier model and the X platform 挑戰者 · 中等 來源：sec.gov
• Starlink Mobile (satellite-to-mobile) 未知 · 中等 來源：sec.gov
• Starlink consumer and enterprise broadband 領先 · 深 來源：sec.gov

• Comirnaty 未知 · 深 來源：sec.gov
• Eliquis 未知 · 低 來源：sec.gov
• Ibrance 未知 · 低 來源：sec.gov
• Padcev 未知 · 中等 來源：sec.gov
• Prevnar family 未知 · 中等 來源：sec.gov
• Vyndaqel family 未知 · 低 來源：sec.gov

編輯先驗，未經回測。

檢視它究竟如何投票 →

編輯先驗，未經回測。

檢視它究竟如何投票 →

編輯先驗，未經回測。

檢視它究竟如何投票 →